CD274 and non-small cell lung carcinoma: Additionally, future studies are needed to extend the application of the PD-L1 index to other solid tumors as well as to other clinical scenarios in lung cancer where the ICIs are being approved, such as adjuvant and neoadjuvant settings in NSCLC and advanced SCLC.